- Citarinostat
-
- $1.00 / 1KG
-
2019-12-23
- CAS:1316215-12-9
- Min. Order: 1g
- Purity: Min98% HPLC
- Supply Ability: g/kg /ton
|
| Citarinostat Basic information |
Product Name: | Citarinostat | Synonyms: | 2-[(2-Chlorophenyl)phenylamino]-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide;Citarinostat;Citarinostat (ACY-241);ACY-241(CITARINOSTAT);2-((2-Chlorophenyl)(phenyl)aMino)-N-(7-(hydroxyaMino)-7-oxoheptyl)pyriMidine-5-carboxaMide;5-Pyrimidinecarboxamide, 2-[(2-chlorophenyl)phenylamino]-N-[7-(hydroxyamino)-7-oxoheptyl]-;HDAC-IN-2;Citarinostat(ACY-241,HDAC-IN-2) | CAS: | 1316215-12-9 | MF: | C24H26ClN5O3 | MW: | 467.95 | EINECS: | | Product Categories: | | Mol File: | 1316215-12-9.mol | |
| Citarinostat Chemical Properties |
density | 1.293±0.06 g/cm3(Predicted) | storage temp. | Store at -20°C | solubility | ≥23.4 mg/mL in DMSO; insoluble in H2O; ≥4.87 mg/mL in EtOH with ultrasonic | form | solid | pka | 9.47±0.20(Predicted) | color | White to off-white |
| Citarinostat Usage And Synthesis |
Description | ACY-241 is an inhibitor of histone deacetylase 6 (HDAC6; IC50 = 2.6 nM). It is selective for HDAC6 over HDAC1-3, HDAC7, and HDAC9 (IC50s = 35, 45, 46, 7,300, and 137 nM, respectively), as well as HDAC4, HDAC5, and HDAC9 (IC50 = >20,000 nM for all). It reduces proliferation of A2780, TOV-21G, and MDA-MB-231 cells when used at a concentration of 3 μM and completely inhibits it and induces apoptosis at a concentration of 10 μM. ACY-241, when used in combination with paclitaxel , inhibits proliferation in MiaPaCa-2, TOV-21G, and T47D cells. It also reduces tumor growth in a MiaPaCa-2 mouse xenograft model when administered at a dose of 50 mg/kg in combination with paclitaxel. ACY-241, in combination with the somatostatin receptor agonist pasireotide , reduces hepatorenal cystogenesis in a rat model of polycystic liver disease. | Uses | Citarinostat is a HDAC inhibitor. | references | [1]. quayle sn, almeciga-pinto i, tamang d, et al. selective hdac inhibition by ricolinostat (acy-1215) or acy-241 synergizes with imid® immunomodulatory drugs in multiple myeloma (mm) and mantle cell lymphoma (mcl) cells. in: proceedings of the 106th annual meeting of the american association for cancer research, 2015, philadelphia, pa. philadelphia (pa): aacr; cancer res 2015;75(15 suppl):abstract nr 5380. [2]. huang p, almeciga-pinto i, jordan m, et al. selective hdac inhibition by acy-241 enhances the activity of paclitaxel in solid tumor models. in: proceedings of the 2015 aacr-nci-eortc international conference on molecular targets and cancer therapeutics; 2015 nov 5-9; boston, massachusetts. philadelphia (pa): aacr |
| Citarinostat Preparation Products And Raw materials |
|